CD274 and non-small cell lung carcinoma: Current immunotherapy agents used in NSCLC inhibit the checkpoint proteins that down-regulate T cells, including programmed death-1 (PD-1)/PD-L1 and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (7).